



Reporting and funding opportunities in HORIZON 2020

Mark Goldammer
Directorate E “Health”
DG Research & Innovation
European Commission

PAINCAGE General Assembly meeting July 1-2, 2015

Periodic Reports



The periodic report shall be transmitted:

- “ through the coordinator to the EC
- “ via the Participant Portal
- “ including FORM C
- “ The Form C must be signed by the authorised person(s) within the beneficiary's organisation

There is a guideline 'Guidance Notes on Project Reporting'

http://ec.europa.eu/research/participants/data/ref/fp7/89692/project-reporting_en.pdf

& a 'Template for Periodic Report' (EN 123392):

http://ec.europa.eu/research/participants/portal/desktop/en/funding/reference_docs.html#fp7



Periodic Reports



The **Publishable Summary** is a standalone document, understandable without further explanations or information.

- ” Major tasks and achievements
- ” since the beginning of the project
- ” and (overall) objectives
- ” in a language also understandable for lay persons
→ enabling direct publication
- ” best no longer than 1 page
- Concise!

(It's not a copy and paste exercise from the TA & periodic report...)



Periodic Reports



The periodic report should include only tasks & results achieved during the respective reporting period,

- ” no historical overview,
- ” no results achieved before,
- ” nor outside the project (according to TA)

The periodic report should be a concise, complete and honest overview of:

- ” progress of the work
- ” achievements
- ” and problems!



Periodic Reports



For each work package, except project management, which will be reported in section 3.2.3, please provide the following information:

- A summary of progress towards objectives and details for each task;
- Highlight clearly significant results;
- If applicable, explain the reasons for deviations from Annex I and their impact on other tasks as well as on available resources and planning;
- If applicable, explain the reasons for failing to achieve critical objectives and/or not being on schedule and explain the impact on other tasks as well as on available resources and planning (the explanations should be coherent with the declaration by the project coordinator) ;
- a statement on the use of resources, in particular highlighting and explaining deviations between actual and planned person-months per work package and per beneficiary in Annex 1 (Description of Work);
- If applicable, propose corrective actions.



Periodic Reports



Also the **Periodic Report** is a standalone document.

- It is not possible to refer to other documents e.g. deliverables!
- ” Avoid redundancy between deliverables and periodic reports.
- ” *(Deliverables have the format of a separated report.)*

The periodic report has to

- ” include the relevant details **but**,
- ” to be as short as possible (avoid unnecessary, lengthy explanations and justifications)
- be concise!



Periodic Reports



3.2.3 Project management during the period

Please use this section to summarise management of the consortium activities during the period. Management tasks are indicated in Articles II.2.3 and Article II.16.5 of the Grant Agreement.

Amongst others, this section should include the following:

- Consortium management tasks and achievements;
- Problems which have occurred and how they were solved or envisaged solutions;
- Changes in the consortium, if any;
- List of project meetings, dates and venues;
- Project planning and status;
- Impact of possible deviations from the planned milestones and deliverables, if any;
- Any changes to the legal status of any of the beneficiaries, in particular non-profit public bodies, secondary and higher education establishments, research organisations and SMEs;
- Development of the Project website, if applicable;

The section should also provide short comments and information on co-ordination activities during the period in question, such as communication between beneficiaries, possible co-operation with other projects/programmes etc.

For Grant Agreements related to infrastructures (Annex III to the Grant Agreement), the access provider shall include a section in the periodic reports on the access activity, indicating the membership of the selection panel as well as the amount of access provided to the user groups, with the description of their work, and the names and home institutions of users.

Periodic Reports



General recommendations

- “ Adhere strictly to deadlines of 60 days – it’s a contractual obligation.
- “ Do not submit incomplete reports!
- “ Follow the structure of periodic reports given in the guidance notes & template

Plan ahead

- “ Alert all partners to importance of timely submission
- “ Discuss reporting modalities early with partners





Funding opportunities in HORIZON 2020 – Brain research



Horizon 2020: 3 priorities

- “ European Research Council
- “ Future and Emerging Technologies
- “ Marie Skłodowska-Curie actions
- “ Research infrastructures

- “ Leadership in enabling and industrial technologies
- “ Access to risk finance
- “ Innovation in SMEs

• ***Excellent science***

• ***Industrial leadership***

• ***Societal challenges***

“ **Health, demographic change and wellbeing**

- “ Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy
- “ Secure, clean and efficient energy
- “ Smart, green and integrated transport
- “ Climate action, environment, resource efficiency and raw materials
- “ Inclusive, innovative and reflective societies
- “ Secure societies
- “ Science with and for society
- “ Spreading excellence and widening participation

7 Focus Areas



7. Health, demograph change and wellbeing

Understanding health, ageing & disease

**Effective health promotion, disease prevention,
preparedness and screening**

Improving diagnosis

Innovative treatments and technologies

Advancing active and healthy ageing

Integrated, sustainable, citizen-centred care

**Improving health information, data exploitation and
providing an evidence base for health policies and regulation**



- PHC-01-2014:** *Understanding health, ageing and disease: determinants, risk factors and pathways*
- PHC-05-2014:** *Health promotion and disease prevention: translating 'omics' into stratified approaches*
- PHC-06-2014:** *Evaluating existing screening and prevention programmes*
- PHC-10-2014:** *Development of new diagnostic tools and technologies: in vitro devices, assays and platforms*
- PHC-13-2014:** *New therapies for chronic non-communicable diseases*
- PHC-17-2014:** *Comparing the effectiveness of existing healthcare interventions in the elderly*
- PHC-23-2014:** *Developing and comparing new models for safe and efficient, prevention oriented health and care systems*
- PHC-32-2014:** *Advancing bioinformatics to meet biomedical and clinical needs*

- ” Adapting to an ageing population
- ” Personalised medicine
- ” Translational research
- ” Clinical trials
- ” CER and costs

Further Opportunities



IMI 2

The Innovative Medicines Initiative is a Public-private partnership between the EU and pharmaceutical industry launched in 2008

- Strategic research agenda: broader scope
'The right prevention and treatment for the right patient at the right time'
- Neurodegenerative diseases and psychiatric diseases among the health priorities identified
- Based on WHO priority medicines report
- Indicative IMI 2 - Call 5
→ 4 topics related to brain research



IMI 2

Indicative topics related to brain

topic 3: Inflammation and AD: modulating microglia function
– focussing on TREM2 and CD33

topic 4: Understanding the role of amyloid biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment

topic 5: Evolving models of patient engagement and access for earlier identification of Alzheimer's disease: phased expansion study

topic 6: ApoE biology to validated Alzheimer's disease targets

<http://www.imi.europa.eu/content/home>



Further Opportunities



JPND transnational calls

*Joint Programming initiative on Neurodegenerative Disease Research (JPND):
member-states led initiative (28 countries, FR coordinates)*

2015: Longitudinal Cohort Approaches,
Advanced Experimental Models,
Risk and Protective Factors

€40 million total budget,
incl. €10 million from the EC

The evaluation of the 2015 call is underway

Other annual transnational calls will be launched

*Alzheimer's disease and
other dementias
Parkinson's disease and
PD-related disorders
Prion disease
Motor neurone diseases
Huntington's Disease
Spinocerebellar ataxia
Spinal muscular atrophy*

<http://www.neurodegenerationresearch.eu/>

Further Opportunities



NEURON II transnational calls

Network of European funding for Neuroscience research: member-states led initiative (16 countries, DE coordinates) - neuroscience, neurology, psychiatry

2015:

- ☐ European Research Projects on Neurodevelopmental Disorders
- ☐ European Research Projects on Ethical, Legal, and Social Aspects (ELSA) of Neuroscience

€10 million total budget

The evaluation of the 2015 call is underway

Other annual transnational calls will be launched

<http://www.neurodegenerationresearch.eu/>





Horizon 2020

Next steps-Work Programme 2016-2017

- **2016 call expected to be published end 2015**
- **Submission deadline expected in the first quarter 2016**

<http://ec.europa.eu/research/participants/portal/desktop/en/home.html>





Thank you

www.ec.europa.eu/research/health

www.ec.europa.eu/research/horizon2020


Further Opportunities



Future & Emerging Technologies Flagship Model

Science-driven, large-scale R&D initiatives addressing a grand S&T challenge

- " 10 years research roadmap
- " budget of 1 billion €
- " EU and national funding



ec.europa.eu/digital-agenda/en/fet-flagships

The Human Brain Project


~100 M€/year – started Oct 2013

www.humanbrainproject.eu



A federated ICT infrastructure for neuroscience, personalised medicine and future computing

- " To catalyse a collaborative European effort for understanding the brain and its diseases and for emulating its computational capabilities
- " More than 400 scientists from 112 institutions from 24 countries




Research
Innovation

FP7 Brain




Brain research (2007-2013)

Collaborative research / Frontier research / Training and mobility



€3 billion



Over 19,000 Connections

Example: RIA



closed

PHC 13 – 2014 New therapies for chronic non-communicable diseases

Specific challenge: *Chronic non-communicable diseases represent a significant burden on individuals and healthcare systems. Innovative, cost effective therapeutic approaches are required to provide the best quality of care when prevention fails. While a considerable amount of knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.*



PHC 13 – 2014 New therapies for chronic non-communicable diseases

Scope: *Clinical trial(s) supporting proof of concept in humans to assess the potential clinical efficacy of the novel therapeutic concept(s) and / or optimisation of available therapies (e.g. drug repurposing). The application may build on pre-existing pre-clinical research and additional results from large scale databases. A concise feasibility assessment justified by available published and preliminary results and supporting data should also be provided. Considerations of effectiveness and potential clinical benefit (possibly including real world data) should be integrated in the application if relevant.*

Example: RIA



closed

PHC 13 – 2014 New therapies for chronic non-communicable diseases

Expected impact:

New therapeutic strategies, adapted where relevant to the differing needs of men and women, with the highest potential to generate advances in clinical practice for chronic diseases, including multi- or comorbidity, ready for further development.

Early exclusion of candidate strategies unlikely to succeed. Contribute to the improvement of the therapeutic outcome of major chronic health issues with significant impact on burden of diseases both for individual patients and for health care systems.



PHC 12 : Clinical research for the validation of biomarkers and/or diagnostic medical devices

- ADDIA: "Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer's disease" (Amoneta Diagnostics)*
- But also on: myocardial **infarction**, lung **cancer**, pancreatic **cancer**, cervical **cancer**, colorectal **cancer**, **glioma**, bladder **cancer**, rheumatoid **arthritis**, dental **carries**, **respiratory** distress syndrome, **corneal** diseases*